Schonfeld Strategic Advisors Adds $12M in BioCryst Pharmaceuticals, Inc. ($BCRX)

Schonfeld Strategic Advisors has significantly increased its investment in BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). According to its latest 13F filing with the SEC, Schonfeld added 1,196,244 shares of BioCryst, boosting its stake by a remarkable 845.7%. This brings its total holdings to 1,337,693 shares valued at approximately $12.1 million as of the end of the reporting period.

What Changed in Schonfeld Strategic Advisors' BioCryst Pharmaceuticals Position

Schonfeld Strategic Advisors' move involved a substantial increase from its previous holding of 141,449 shares to a current total of 1,337,693 shares. This change reflects an addition of 1,196,244 shares, representing a significant vote of confidence in BioCryst Pharmaceuticals.

Other Institutional Activity in BioCryst Pharmaceuticals

Other major institutional investors have also been active in BioCryst Pharmaceuticals. BlackRock, Inc. increased its holdings by 1,513,197 shares, ending with 22,650,988 shares valued at about $215.6 million. RA Capital Management, L.P. maintained its position with 15,827,186 shares worth $150.7 million. Deerfield Management Company, L.P. grew its stake by 697,000 shares, bringing its total to 15,038,000 shares valued at $143.2 million. Meanwhile, State Street Corp added 1,135,149 shares, resulting in 12,208,360 shares worth approximately $116.2 million.

BioCryst Pharmaceuticals, Inc. Stock Up 1.8%

Shares of BioCryst Pharmaceuticals (NasdaqGS: BCRX) are trading near $9.06. The company, which operates in the healthcare sector as a specialty and generic drug manufacturer, has a market cap of $2.3 billion. It has a forward P/E ratio of 13.3 and a beta of 0.565, indicating lower volatility compared to the market. The stock's 52-week range is between $6.00 and $10.32, with a 50-day moving average of $8.95 and a 200-day moving average of $7.93.

Recent Earnings

BioCryst Pharmaceuticals reported revenue of $885.7 million, reflecting a growth of 7.5%. Despite this, the company remains unprofitable, with a net margin of -51.7%. The company is expected to announce its next earnings on August 3, 2026.

Insider Buying and Selling at BioCryst Pharmaceuticals, Inc.

Several insiders have recently purchased shares of BioCryst Pharmaceuticals. On June 11, 2026, Steven Galson and Machelle Sanders each bought 33,540 and 15,294 shares, respectively. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On May 7, 2026, Citizens maintained its 'buy' rating on BioCryst Pharmaceuticals with a price target of $28. Similarly, Wedbush also maintained its 'buy' rating with a target of $21. Needham reiterated its 'buy' rating with a $16 target on May 6, 2026. The consensus among analysts remains positive, with an average price target of $21.3 based on 10 analyst opinions.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a biotechnology company based in Durham, North Carolina. It focuses on developing and commercializing medicines for rare diseases such as hereditary angioedema (HAE). The company markets products like RAPIVAB for influenza and ORLADEYO for HAE. BioCryst is also involved in developing treatments for other conditions, including netherton syndrome and diabetic macular edema. Led by CEO Charles K. Gayer, BioCryst employs around 435 people.

Bottom Line

Schonfeld Strategic Advisors' significant increase in its BioCryst Pharmaceuticals holdings highlights the fund's confidence in the company's potential. BioCryst's ongoing development of treatments for rare diseases and its strategic partnerships continue to attract institutional interest. Investors should note that 13F filings reflect past positions and may not represent current holdings.